Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This ensures the APIs quality, potency, and purity, crucial for the safety and efficacy of compounded medications
Transition probabilities between health states were sourced from the UK Prospective Diabetes Study Outcomes Model (UKPDS 82) and the SUSTAIN 7 clinical trial, while health utility values were obtained from published literature using the Chinese EQ-5D-5L value set
Drugs Today
US$ 27.11
:max_bytes(150000):strip_icc()/Health-GLP1-pill-vs-shot-137cf589ddca421bb0aef5c5d7aec64a.png)
:max_bytes(150000):strip_icc()/Wegovy-pill-pic-590ed53ed3304ba8b2388f9d78886dae.png)
US$ 26.86
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 24.80
US$ 23.90
US$ 21.40
